First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
May 13, 2025
In a BridgeBio Pharma, Inc., news release distributed by Globe Newswire about an early intervention for an inherited cardiovascular condition called transthyretin amyloid disease, Ahmad Masri, M.D., says, “I am hopeful that we can fill the significant gap in care for asymptomatic carriers of a genetic variant by providing potential preventative intervention early with resulting greater clinical benefit than addressing the disease at a later stage.”